https://www.selleckchem.com/products/sj6986.html
To determine whether the punctuated administration of low-dose rituximab, temporally linked to B-cell hyperrepopulation (defined when the return of CD19 B cells approximates 40%-50% of baseline levels as measured before alemtuzumab treatment inception), can mitigate alemtuzumab-associated secondary autoimmunity. In this hypothesis-driven pilot study, 10 patients received low-dose rituximab (50-150 mg/m ), a chimeric anti-CD20 monoclonal antibody, after either their first or second cycles of alemtuzumab. These patients were then routinely
Like
Comment
Share
